Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomePreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Gains from Sales and Divestitures (2018 - 2020)

vTv Therapeutics (VTVT) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $11667.0 as the latest value for Q4 2020.

  • Quarterly Gains from Sales and Divestitures changed 0.01% to $11667.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $11667.0 through Dec 2020, changed 0.01% year-over-year, with the annual reading at $11667.0 for FY2020, 0.01% changed from the prior year.
  • Gains from Sales and Divestitures hit $11667.0 in Q4 2020 for vTv Therapeutics, roughly flat from $11667.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $11667.0 in Q2 2018 to a low of $11666.0 in Q1 2018.
  • Historically, Gains from Sales and Divestitures has averaged $11666.6 across 3 years, with a median of $11667.0 in 2018.
  • Biggest five-year swings in Gains from Sales and Divestitures: fell 0.01% in 2019 and later rose 0.01% in 2020.
  • Year by year, Gains from Sales and Divestitures stood at $11667.0 in 2018, then decreased by 0.01% to $11666.0 in 2019, then rose by 0.01% to $11667.0 in 2020.
  • Business Quant data shows Gains from Sales and Divestitures for VTVT at $11667.0 in Q4 2020, $11667.0 in Q3 2020, and $11667.0 in Q2 2020.